While this has been a pretty good year for the biotech industry, 2013 has been a spectacular year for San Diego’s biotech industry. During a three-month period, San Diego’s Regulus Therapeutics raised $51 million through an IPO that generated $81 million in gross proceeds; Johnson & Johnson acquired San Diego’s Aragon Pharmaceuticals for $650 million (with an additional $350 million in potential development milestone payments), and Cubist Pharmaceuticals acquired San Diego’s Trius Therapeutics for about $705 million. Biocom has invited the CEOs of each company to share their perspective on what went right. More information and online registration is here.